Intravenous immunoglobulin and anti-RhD therapy in the management of immune thrombocytopenia.
Intravenous immunoglobulin and intravenous anti-D are common therapies in the management of patients with immune thrombocytopenia (ITP). Both are pooled plasma products and both result in an increase in the platelet count in approximately 60% to 70% of patients with ITP. Despite immediate increases in the platelet count, the duration of response is limited, with platelet increments lasting between 2 and 4 weeks. Infusion reactions are common but adverse events rare. Although responses are similar, human and murine data suggest that the mechanisms of action of these treatments are complex and likely different.
Cooper
Nichola
N
Department of Haematology, Hammersmith Hospital, Imperial Health Care NHS Trust, Du Cane Road, London W12 OHS, UK. n.cooper@imperial.ac.uk
D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000276:immunology / Q000628:therapy*; D018029:Rho(D) Immune Globulin / Q000627:therapeutic use*
D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D018029:Rho(D) Immune Globulin